{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:16:52Z","timestamp":1783624612620,"version":"3.55.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2024.01.048","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:44:43Z","timestamp":1705797883000},"page":"1013-1021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Implications of vaccine non-specific effects on licensure of new vaccines"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9939-5855","authenticated-orcid":false,"given":"Grant","family":"Munkwase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2024.01.048_b0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.chom.2011.04.006","article-title":"Perspective trained immunity: a memory for innate host defense","volume":"9","author":"Netea","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2024.01.048_b0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-genom-090711-163747","article-title":"Evolution of the immune system in the lower vertebrates","volume":"13","author":"Boehm","year":"2012","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.048_b0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/eci.12132","article-title":"Training innate immunity: The changing concept of immunological memory in innate host defence","volume":"43","author":"Netea","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.vaccine.2024.01.048_b0020","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1376595","article-title":"The Memories of NK cells: innate-adaptive immune intrinsic crosstalk","volume":"2016","author":"Gabrielli","year":"2016","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0025","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.chom.2020.05.014","article-title":"BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment","volume":"28","author":"Cirovic","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.048_b0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1189\/jlb.5RI0315-096R","article-title":"Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines","volume":"98","author":"Blok","year":"2015","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2024.01.048_b0035","unstructured":"Gong W, Mao Y, Li Y, Qi Y. BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents; no. January, 2020."},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.048_b0040","first-page":"4","article-title":"Unravelling the nature of non-specific effects of vaccines\u2014A challenge for innate immunologists","volume":"28","author":"Jarlov","year":"2016","journal-title":"Semin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/ijms19020456","article-title":"Infectious agents as stimuli of trained innate immunity","volume":"19","author":"Rusek","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2024.01.048_b0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fimmu.2019.00013","article-title":"Mechanisms of trained innate immunity in oxLDL primed human coronary smooth muscle cells","volume":"10","author":"Schnack","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7774\/cevr.2015.4.1.46","article-title":"Clinical vaccine development","volume":"4","author":"Chung","year":"2015","journal-title":"Clin Exp Vaccine Res"},{"issue":"52","key":"10.1016\/j.vaccine.2024.01.048_b0060","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","article-title":"Vaccine development: From concept to early clinical testing","volume":"34","author":"Cunningham","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/all.14868","article-title":"Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe","volume":"77","author":"Wagner","year":"2022","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.048_b0070","first-page":"509","article-title":"Vaccine development: from laboratory to policy","volume":"49","author":"Park","year":"2020","journal-title":"Peadiatric Ann"},{"key":"10.1016\/j.vaccine.2024.01.048_b0075","unstructured":"Cichutek KSP, Epstein J, Griffiths E, Hindawi S, Jivapaisarnpong T, Klein H, et al. WHO expert committe on biological standardization sixty-sevent report, vol. 1004; 2017."},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.048_b0080","first-page":"e13261","article-title":"Trained immunity and host-pathogen interactions","volume":"22","author":"Peignier","year":"2020","journal-title":"CellMicrobiol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.chom.2012.06.006","article-title":"Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes","volume":"12","author":"Quintin","year":"2012","journal-title":"Cell Host Microbe"},{"issue":"43","key":"10.1016\/j.vaccine.2024.01.048_b0090","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Gu\u00e9rin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2024.01.048_b0095","unstructured":"Arts RJW. Immunometabolic pathways regulating innate immune adaptation Rob Johannes Wilhelmus Arts; 2022."},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.048_b0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jlb.49.4.342","article-title":"Effect of soluble aminated \u03b2-1,3-D-polyglucose on human monocytes: Stimulation of cytokine and prostaglandin E2 production but not antigen-presenting function","volume":"49","author":"Doita","year":"1991","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0928-8244(02)00460-1","article-title":"\u03b2-Glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections","volume":"35","author":"Yun","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2024.01.048_b0110","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.3389\/fimmu.2021.723393","article-title":"Trained immunity confers prolonged protection from listeriosis","volume":"12","author":"Th\u00e9roude","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.048_b0115","doi-asserted-by":"crossref","first-page":"pp","DOI":"10.1016\/j.celrep.2019.08.004","article-title":"\u03b2-Glucan-induced trained immunity protects against leishmania braziliensis infection: a crucial role for IL-32","volume":"28","author":"Dos Santos","year":"2019","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.048_b0120","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1172\/JCI97508","article-title":"Mycobacterial growth inhibition is associated with trained innate immunity","volume":"128","author":"Joosten","year":"2018","journal-title":"J Clin Invest"},{"issue":"January","key":"10.1016\/j.vaccine.2024.01.048_b0125","first-page":"1","article-title":"Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19","volume":"14","author":"Du","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.048_b0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/14760584.2021.1938550","article-title":"COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials","volume":"20","author":"Gong","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0062-8","article-title":"Long-term reduction in hyperglycemia in advanced type 1 diabetes: The value of induced aerobic glycolysis with BCG vaccinations","volume":"3","author":"K\u00fchtreiber","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.048_b0140","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/joim.13050","article-title":"Benefits of BCG-induced metabolic switch from oxidative phosphorylation to aerobic glycolysis in autoimmune and nervous system diseases","volume":"288","author":"Faustman","year":"2020","journal-title":"J Intern Med"},{"issue":"SEP","key":"10.1016\/j.vaccine.2024.01.048_b0145","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0150","first-page":"1","article-title":"Friend retrovirus infection induces the development of memory-like natural killer cells 11 Medical and Health Sciences 1107 Immunology","volume":"15","author":"Littwitz-Salomon","year":"2018","journal-title":"Retrovirology"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.048_b0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2024.01.048_b0160","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.3389\/fimmu.2018.02869","article-title":"Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations","volume":"9","author":"Uthayakumar","year":"2018","journal-title":"Front Immunol"},{"issue":"March","key":"10.1016\/j.vaccine.2024.01.048_b0165","article-title":"Evidence of increase in mortality after the introduction of diphtheria\u2013tetanus\u2013pertussis vaccine to children aged 6\u201335 months in Guinea-Bissau: a time for reflection?","volume":"6","author":"Aaby","year":"2018","journal-title":"Front Public Heal"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.048_b0170","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/trstmh\/trw073","article-title":"Is diphtheria-tetanus-pertussis (DTP) associated with increased female mortality? A meta-analysis testing the hypotheses of sex-differential non-specific effects of DTP vaccine","volume":"110","author":"Aaby","year":"2016","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.01.048_b0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ebiom.2017.01.041","article-title":"The introduction of diphtheria-tetanus-pertussis and oral polio vaccine among Young Infants in an urban African community: a natural experiment","volume":"17","author":"Mogensen","year":"2017","journal-title":"EBioMedicine"},{"issue":"9376","key":"10.1016\/j.vaccine.2024.01.048_b0180","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(03)13771-3","article-title":"Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: Reanalysis of West African studies","volume":"361","author":"Aaby","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.048_b0185","article-title":"Association of BCG, DTP, and measles containing vaccines with childhood mortality: Systematic review","volume":"355","author":"Higgins","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.01.048_b0190","unstructured":"World Health Organization (WHO), \u201cWeekly epidemiological record No.29,\u201d Geneva; 2004. [Online]. Available: https:\/\/cdn.who.int\/media\/docs\/default-source\/a-future-for-children\/wer7929_2004_vol79-29.pdf?sfvrsn=b1fd77c5_1&download=true."},{"key":"10.1016\/j.vaccine.2024.01.048_b0195","unstructured":"World Health Organization (WHO), \u201cWeekly epidemiological record No.21,\u201d Geneva; 2014. [Online]. Available: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/2014\/april\/apr2014wer8921.pdf?sfvrsn=83c7d7b1_3."},{"key":"10.1016\/j.vaccine.2024.01.048_b0200","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.cmi.2019.08.011","article-title":"Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies","volume":"25","author":"Aaby","year":"2019","journal-title":"Clin Microbiol Infect J"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.048_b0205","doi-asserted-by":"crossref","first-page":"e1009928","DOI":"10.1371\/journal.ppat.1009928","article-title":"Induction of trained immunity by influenza vaccination - impact on COVID-19","volume":"17","author":"Debisarun","year":"2021","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.048_b0210","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm1077","article-title":"A role for Streptococcus pneumoniae in virus-associated pneumonia","volume":"10","author":"Madhi","year":"2004","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0215","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.vaccine.2019.10.005","article-title":"Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017\u20132018 influenza season","volume":"38","author":"Wolff","year":"2020","journal-title":"Vaccine"},{"issue":"21\u201322","key":"10.1016\/j.vaccine.2024.01.048_b0220","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/S0264-410X(03)00181-6","article-title":"BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: A non-specific beneficial effect of BCG?","volume":"21","author":"Garly","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0225","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/jir240","article-title":"Randomized trial of BCG vaccination at birth to low- birth-weight children: beneficial nonspecific effects in the neonatal period?","volume":"204","author":"Aaby","year":"2011","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.048_b0230","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/pr.2016.142","article-title":"childhood infections: a randomized, clinical multicenter trial","volume":"80","author":"Jeppesen","year":"2016","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0235","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1525-1470.2012.01848.x","article-title":"Treatment of common and plane warts in children with topical viable bacillus Calmette-Guerin","volume":"30","author":"Salem","year":"2013","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.048_b0240","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4103\/0378-6323.193623","article-title":"Immunotherapy in viral warts with intradermal Bacillus Calmette-Guerin vaccine versus intradermal tuberculin purified protein derivative: A double-blind, randomized controlled trial comparing effectiveness and safety in a tertiary care center in Eastern I","volume":"83","author":"Podder","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"10.1016\/j.vaccine.2024.01.048_b0245","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1473-3099(20)30994-4","article-title":"The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi","volume":"21","author":"Glynn","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.048_b0250","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/infdis\/jiv332","article-title":"BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study","volume":"212","author":"Leentjens","year":"2015","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0255","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00356-23","article-title":"BCG vaccination of health care workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomized placebo-controlled trial","volume":"14","author":"Claus","year":"2023","journal-title":"MBio"},{"issue":"17","key":"10.1016\/j.vaccine.2024.01.048_b0260","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1056\/NEJMoa2212616","article-title":"Randomized trial of BCG vaccine to protect against Covid-19 in health care workers","volume":"388","author":"Pittet","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.048_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101414","article-title":"Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial","volume":"vol. 48","author":"Upton","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0270","first-page":"1","article-title":"A multi-centre, randomised, double-blind, placebo-controlled phase III clinical trial evaluating the impact of BCG re-vaccination on the incidence and severity of SARS-CoV-2 infections among symptomatic healthcare professionals during the COVID-19 pandemi","volume":"11","author":"Zapolnik","year":"2023","journal-title":"Vaccines"},{"issue":"July","key":"10.1016\/j.vaccine.2024.01.048_b0275","first-page":"1","article-title":"ACTIVATE-2: a double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk","volume":"13","author":"Tsilika","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.048_b0280","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1473-3099(20)30653-8","article-title":"BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial","volume":"21","author":"Prentice","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.048_b0285","first-page":"2020","article-title":"Correlation between universal BCG vaccination policy and reduced mortality for COVID-19","author":"Miller","year":"2020","journal-title":"medRxiv"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.048_b0290","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijtb.2020.10.012","article-title":"Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?","volume":"68","author":"Gong","year":"2021","journal-title":"Indian J Tuberc"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0295","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7774\/cevr.2020.9.2.179","article-title":"Current national policies for infant universal bacille calmettegu\u00e9rin vaccination were associated with lower mortality from coronavirus disease 2019","volume":"9","author":"Ebina-Shibuya","year":"2020","journal-title":"Clin Exp Vaccine Res"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-80787-z","article-title":"The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning","volume":"11","author":"Brooks","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0305","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/08830185.2021.1922685","article-title":"Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic","volume":"41","author":"Aspatwar","year":"2022","journal-title":"Int Rev Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0310","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/JCI145545","article-title":"BCG vaccination in health care providers and the protection against COVID-19","volume":"131","author":"Netea","year":"2021","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0315","doi-asserted-by":"crossref","first-page":"pp","DOI":"10.1172\/JCI145157","article-title":"BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers","volume":"131","author":"Rivas","year":"2021","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.vaccine.2024.01.048_b0320","doi-asserted-by":"crossref","first-page":"e1007327","DOI":"10.1371\/journal.ppat.1007327","article-title":"The calendar of epidemics: Seasonal cycles of infectious diseases","volume":"14","author":"Elvira","year":"2018","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.048_b0325","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1469-0691.2012.03968.x","article-title":"Seasonality of viral infections: mechanisms and unknowns","volume":"18","author":"Fisman","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.01.048_b0330","unstructured":"Centre for Disease Control and Prevention(CDC), \u201cImmunization Schedules Child and Adolescent Immunization Schedule Birth to 15 Months,\u201d CDC; 2022. https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html."},{"key":"10.1016\/j.vaccine.2024.01.048_b0335","unstructured":"World Health Organization (WHO), \u201cWHO recommendations for routine immunization - summary tables.\u201d https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/policies\/who-recommendations-for-routine-immunization---summary-tables."},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0163-4453(84)93192-X","article-title":"Measles vaccination and reduction in child mortality: A community study from Guinea-Bissau","volume":"8","author":"Aaby","year":"1984","journal-title":"J Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.048_b0345","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1099\/0022-1317-80-7-1599","article-title":"Measles virus-induced immunosuppression in vitro is associated with deregulation of G 1 cell cycle control proteins","volume":"80","author":"Engelking","year":"1999","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.048_b0350","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1566524013363960","article-title":"Measles virus induced immunosuppression: targets and effector mechanisms","volume":"1","author":"Niewiesk","year":"2001","journal-title":"Curr Mol Med"},{"issue":"7003","key":"10.1016\/j.vaccine.2024.01.048_b0355","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bmj.311.7003.481","article-title":"Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries","volume":"311","author":"Aaby","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.01.048_b0360","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c6495","article-title":"Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial","volume":"341","author":"Aaby","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.01.048_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eclinm.2022.101467","article-title":"Effect of early two-dose measles vaccination on childhood mortality and modification by maternal measles antibody in Guinea-Bissau, West Africa: A single-centre open-label randomised controlled trial","volume":"49","author":"Nielsen","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.01.048_b0370","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2023.05.011","article-title":"Overall effect of a campaign with measles vaccine on the composite outcome mortality or hospital admission: A cluster-randomized trial among children aged 9\u201359 months in rural Guinea-Bissau","volume":"134","author":"Varma","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.048_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0177547","article-title":"Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau","volume":"12","author":"Hansen","year":"2017","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.vaccine.2024.01.048_b0380","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.vaccine.2018.02.104","article-title":"No effect of an additional early dose of measles vaccine on hospitalization or mortality in children: A randomized controlled trial","volume":"36","author":"Schoeps","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.048_b0385","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jama.2014.470","article-title":"Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections","volume":"311","author":"S\u00f8rup","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.048_b0390","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/cid\/cix442","article-title":"Risk of nontargeted infectious disease hospitalizations among US children following inactivated and live vaccines, 2005\u20132014","volume":"65","author":"Bardenheier","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.048_b0395","article-title":"Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands","volume":"358","author":"Tielemans","year":"2017","journal-title":"BMJ"},{"issue":"45","key":"10.1016\/j.vaccine.2024.01.048_b0400","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.15585\/mmwr.mm7045a1","article-title":"Progress toward regional measles elimination-worldwide, 2000\u20132020","volume":"70","author":"Dixon","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2024.01.048_b0405","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1016\/j.vaccine.2004.02.009","article-title":"Oral polio vaccination and low case fatality at the paediatric ward in Bissau, Guinea-Bissau","volume":"22","author":"Aaby","year":"2004","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.048_b0410","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/archdischild-2011-300646","article-title":"Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial","volume":"97","author":"Aaby","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2024.01.048_b0415","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ebiom.2017.01.041","article-title":"The introduction of diphtheria-tetanus-pertussis and oral polio vaccine among young infants in an urban African community: a natural experiment","volume":"17","author":"Wengel","year":"2017","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.048_b0420","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1365-3156.2005.01434.x","article-title":"Evaluation of non-specific effects of infant immunizations on early infant mortality in a southern Indian population","volume":"10","author":"Moulton","year":"2005","journal-title":"Trop Med Int Heal"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofv204","article-title":"Oral polio vaccination and hospital admissions with non-polio infections in Denmark: Nationwide retrospective cohort study","volume":"3","author":"S\u00f8rup","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.048_b0430","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/cid\/civ617","article-title":"The effect of oral polio vaccine at birth on infant mortality: a randomized trial","volume":"61","author":"Lund","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.048_b0435","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/cix354","article-title":"Nonspecific effects of oral polio vaccine on diarrheal burden and etiology among Bangladeshi infants","volume":"65","author":"Upfill-Brown","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"May","key":"10.1016\/j.vaccine.2024.01.048_b0440","first-page":"1","article-title":"Vaccination with oral polio vaccine reduces COVID-19 incidence","volume":"13","author":"Yagovkina","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.01.048_b0445","unstructured":"WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Tech Rep 2004;924:35\u2013102. [Online]. Available: http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/clinical_evaluation\/en\/."},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.048_b0450","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/trstmh\/tru161","article-title":"The heterologous (non-specific) effects of vaccines: implications for policy in high-mortality countries","volume":"109","author":"Shann","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.048_b0455","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01295-3","article-title":"Implications of non-specific effects for testing, approving, and regulating vaccines","volume":"46","author":"Benn","year":"2023","journal-title":"Drug Saf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:32:59Z","timestamp":1759404779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X24000604"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of vaccine non-specific effects on licensure of new vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}